drugset / Trial / NCT01712217
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.
Timeline
- Start
- 2012-10
- Primary completion
- 2016-12
- Completion
- 2017-05-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizotinib | Small molecule | 250 mg | Oral |
| Subject | Onalespib | Small molecule | — | Intravenous |